Atossa Genetics Inc (ATOS) 0.27 $ATOS
Atossa Genetics Initiates Additional Drug Development Program
Marketwired - Tue Jun 07, 7:01AM CDT
Oral Endoxifen for Patients Refractory to Tamoxifen
ATOS: 0.27 (+0.02)
Atossa Genetics to Present at 6th Annual LD Micro Invitational Conference on June 7th, 2016
ACCESSWIRE - Tue May 31, 7:01AM CDT
SEATTLE, WA / ACCESSWIRE / May 31, 2016 / Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that Dr. Steven Quay, President and CEO, would be a featured presenter at the 6th annual LD Micro Invitational on June 7th, 2016 at 9:30am PST, Track 3 at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on June 7 and 8, 2016.
ATOS: 0.27 (+0.02)
Atossa Genetics Announces $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital Fund, LLC
Marketwired - Fri May 27, 7:00AM CDT
SEATTLE, WA--(Marketwired - May 27, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it has entered into a $10 million stock purchase agreement with Aspire Capital Fund, LLC. Under terms of the agreement, after the SEC declares the registration statement related to the transaction effective, Aspire has committed to purchase up to $10 million of Atossa's common stock over 30 months, based on prevailing market prices over a period preceding each sale.
ATOS: 0.27 (+0.02)
Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?
PR Newswire - Thu May 19, 7:50AM CDT
The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:
ATOS: 0.27 (+0.02), AMAG: 27.02 (+0.49), IDXX: 98.07 (+4.56), ALKS: 49.56 (-0.34)
Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update
Marketwire Canada - Thu May 05, 3:01PM CDT
Conference Call to Be Held Today at 4:30 pm Eastern Time
ATOS: 0.27 (+0.02)
Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment
PR Newswire - Wed May 04, 5:42PM CDT
This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 393 pages. The personalized medicine (global & USA) market is presented as follows:
ATOS: 0.27 (+0.02), AMGN: 174.76 (+0.60)
Atossa Genetics to Host First Quarter 2016 Financial Results and Company Update Conference Call on Thursday, May 5, 2016
Marketwired - Tue May 03, 7:00AM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will host a conference call on Thursday May 5, 2016 at 4:30 pm eastern time to review First Quarter ended March 31, 2016 financial results and provide a company update. Following management's formal remarks, there will be a question and answer session.
ATOS: 0.27 (+0.02)
Atossa Genetics Announces 2015 Financial Results and Provides Company Update
Marketwired - Wed Mar 30, 3:01PM CDT
Atossa Genetics Inc. (NASDAQ: ATOS) today announced 2015 financial results and provided an update on recent company developments.
ATOS: 0.27 (+0.02)
Atossa Genetics to Host 2015 Financial Results and Company Update Conference Call on Wednesday, March 30, 2016
Marketwired - Fri Mar 25, 7:00AM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will host a conference call on Wednesday, March 30, 2016 at 4:30 pm eastern time to review 2015 financial results and provide a company update. Following management's formal remarks, there will be a question and answer session.
ATOS: 0.27 (+0.02)
Molecular Diagnostics Cancer Oncology - Global Market Size, Strategy & Forecasts - 2016 to 2019
M2 - Wed Jan 27, 9:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/phchgt/molecular) has announced the addition of the "Molecular Diagnostics Cancer Oncology - Global Market Size, Strategy and Forecasts - 2016 to 2019" report to their offering. A market that just keeps on growing. Molecular Diagnostics is positioned to directly benefit from the explosion in genomics knowledge. A range of dynamic trends are pushing market growth and company valuations. Trends include: - Personalized medicine - Pharmacogenomics - Pathogen evolution - Next generation sequencing - Emergence of new economies with large markets - Greater understanding of the role of genetic material in Disease and Health Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Companies Mentioned: - 14M Genomics - 23andMe - Abbott Laboratories - Abcam - ACT Genomics - Adaptive Biotechnologies - Aegis Sciences - Agena Bioscience - Agendia - Agilent/Dako - AltheaDx - Amarantus - Ariosa Diagnostics - Atossa Genetics - Baylor College of Medicin - Becton, Dickinson & Co. - Biofortuna - Biological Dynamics - BioMerieux - BioReference Laboratories, Inc. - (50 Others) Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Molecular Diagnostics Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summar For more information visit http://www.researchandmarkets.com/research/phchgt/molecular
ATOS: 0.27 (+0.02), ABT: 45.29 (unch), BDX: 176.78 (+0.78)
Global Medical Laboratory Services Strategies, Trends and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/kww8xj/medical) has announced the addition of the "Medical Laboratory Services Strategies, Trends and Forecasts 2016 to 2019 - Global Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Trends like: - changing demographics - emerging economies and global prosperity - biotechnology advances in genetics - pathogen evolution - climate change - globalization - automation Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Medical Laboratory Services Strategies, Trends and Forecasts 2015 to 2019 - Global Version provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. The Future of the Clinical Laboratory Companies Mentioned - 35 of the 100 Companies - 23andMe - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - ACM Medical Laboratory - ACT Genomics - Adaptive Biotechnologies - Adicon Clinical Laboratories, Inc. - Aegis Sciences - Agena Bioscience - Alere Inc - Amarantus - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Atossa Genetics - Aurora Diagnostics, LLC - Baylor College of Medicin - Biofortuna - Biomnis (France) - BioReference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caprion - CareDx - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Claritas Genomics - Claymon Biomnis Laboratories Ltd. - Clinical Reference Laboratory, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Cypher Genomics - Cytogenetics For more information visit http://www.researchandmarkets.com/research/kww8xj/medical
ATOS: 0.27 (+0.02), AXDX: 20.52 (+0.87), ALR: 36.97 (-0.53), ARDX: 10.50 (-0.18)
Global Molecular Diagnostics Market Size, Strategies and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/w2l7rl/molecular) has announced the addition of the "Molecular Diagnostics Global Market Size, Strategies and Forecasts 2016 to 2019 " report to their offering. A market that just keeps on growing. Molecular Diagnostics is positioned to directly benefit from the explosion in genomics knowledge. A range of dynamic trends are pushing market growth and company valuations. Trends like: - personalized medicine - pharmacogenomics - pathogen evolution - next generation sequencing - emergence of new economies with large markets - greater understanding of the role of genetic material in Disease and Health Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. The report data is designed to be used! The unit volumes of tests performed is presented. Use our pricing scenarios or use your own. Project your market share and your price to reliably generate revenue forecasts or understand your own current market share position. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Infectious Disease, Genetic Testing, Oncology Testing. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Molecular Diagnostics Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary Companies Mentioned - 14M Genomics - 23andMe - Abbott Laboratories - Abcam - Accelerate Diagnostics - AltheaDx - Atossa Genetics - Baylor College of Medicin - Becton, Dickinson & Co. - BioReference Laboratories, Inc. - bioM?rieux - Caprion - Cepheid - Claritas Genomics - Cypher Genomics - Cytogenetics - Diagnovus - Enzo Biochem - Epic Sciences - Foundation Medicine - Genomic Health - Genomic Vision - Good Start Genetics - Google - Great Basin Scientific - Grifols - Glyconics - Hologic - Premaitha - QuantRx? Biomedical - Quidel - Qvella - Response Genetics - Roche Molecular Diagnostics - Rosetta For more information visit http://www.researchandmarkets.com/research/w2l7rl/molecular
ATOS: 0.27 (+0.02), ABT: 45.29 (unch), BDX: 176.78 (+0.78), GBSNU: 16.22 (-0.28), FMI: 23.72 (+0.35), ENZ: 6.72 (-0.25), AXDX: 20.52 (+0.87), CPHD: 36.76 (+1.43), HOLX: 38.98 (+0.49), GHDX: 30.34 (+1.31)
Atossa Genetics Completes Sale of Its Wholly-Owned Subsidiary The National Reference Laboratory for Breast Health, Inc.
Marketwired - Thu Dec 17, 7:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS), a healthcare company focused on developing locally-administered pharmaceuticals for the treatment of pre-cancerous conditions and early stage breast cancer, today announced that on December 16, 2015, it entered into a Stock Purchase Agreement with NRL Investment Group, LLC, an unrelated entity. Under the agreement, Atossa sold to the NRL Group 100% of its shares of Common Stock in its wholly-owned subsidiary, the National Reference Laboratory for Breast Health, Inc. (the "NRLBH"
, while retaining 19% ownership through Preferred Stock. Atossa received $50,000 on December 16, 2015, for the sale of the Common Stock and the right to receive, commencing in December 2016, monthly earn-out payments equal to 6% of gross revenue of the NRLBH, up to a total of $10,000,000. Atossa also has the right in four years to sell its Preferred Stock to the NRL Group for the greater of $4,000,000 or fair market value. As a result of the transaction, the NRL Group is taking over the management, operations and related costs of the NRLBH.
ATOS: 0.27 (+0.02)
Atossa Genetics Announces Third Quarter 2015 Financial Results and Provides Company Update
Marketwired - Thu Nov 12, 3:01PM CST
Atossa Genetics, Inc. (NASDAQ: ATOS) today announced third quarter 2015 financial results and provided an update on recent company developments.
ATOS: 0.27 (+0.02)
Atossa Genetics to Announce Third Quarter 2015 Financial Results and Provide a Company Update on Thursday, November 12, 2015
Marketwired - Tue Nov 10, 7:01AM CST
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will issue financial results and corporate developments for the Third Quarter ended September 30, 2015, following the market close on Thursday, November 12, 2015.
ATOS: 0.27 (+0.02)
Global Breast Cancer Pipeline Review 2015
M2 - Tue Nov 03, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/3xkrvl/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Breast Cancer diagnostic tests pipeline products. Scope - Extensive coverage of the Breast Cancer diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Breast Cancer diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Breast Cancer - Pipeline Products under Development by Companies 5 Breast Cancer Companies and Product Overview 6 Breast Cancer- Recent Developments 7 Appendix Companies Mentioned - 35 of the 150 Companies Featured - A&G Pharmaceutical, Inc. - Abbott Diagnostics - Abcodia Ltd. - Abviva, Inc. - Accelerated Medical Diagnostics - Acobiom - Advanced Cell Diagnostics, Inc. - Affichem SA - AIT Austrian Institute of Technology GmbH - Almac Diagnostics Limited - Amarantus Bioscience Holdings, Inc. - AngioGenex, Inc. - Armune BioScience, Inc. - Arno Therapeutics, Inc. - AroCell AB - ArtemixRx - Ascendant Diagnostics, LLC - Assurance Biosciences, Inc. - Atossa Genetics, Inc. - Autoimmune Technologies, LLC - Ayanda Biosystems S.A. - Becton, Dickinson and Company - Bio Gene Ltd. - BioAffinity Technologies, Inc. - Biocrates Life Sciences AG - Biodesix Inc. - BioMarCare Technologies Ltd. - BioMark Diagnostics Inc. - BioMark Technologies Inc. - BioMarker Strategies, LLC - bioMerieux S.A. - Biosceptre (Aust) Pty Ltd - BioSystems International - bioTheranostics, Inc. - Boston College For more information visit http://www.researchandmarkets.com/research/3x...ast_cancer
ATOS: 0.27 (+0.02)
Atossa Genetics names Janet Rose Rea, MSPH as VP Regulatory Affairs and Quality
M2 - Thu Oct 15, 3:05AM CDT
Healthcare company Atossa Genetics (NASDAQ:ATOS) revealed on Wednesday the appointment of Janet Rose Rea, MSPH as VP Regulatory Affairs and Quality with effect from 12 October 2015.
ATOS: 0.27 (+0.02)
Atossa Genetics Initiates Additional Drug Development Program
Marketwired - Tue Jun 07, 7:01AM CDT
Oral Endoxifen for Patients Refractory to Tamoxifen
ATOS: 0.27 (+0.02)
Atossa Genetics to Present at 6th Annual LD Micro Invitational Conference on June 7th, 2016
ACCESSWIRE - Tue May 31, 7:01AM CDT
SEATTLE, WA / ACCESSWIRE / May 31, 2016 / Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that Dr. Steven Quay, President and CEO, would be a featured presenter at the 6th annual LD Micro Invitational on June 7th, 2016 at 9:30am PST, Track 3 at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on June 7 and 8, 2016.
ATOS: 0.27 (+0.02)
Atossa Genetics Announces $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital Fund, LLC
Marketwired - Fri May 27, 7:00AM CDT
SEATTLE, WA--(Marketwired - May 27, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it has entered into a $10 million stock purchase agreement with Aspire Capital Fund, LLC. Under terms of the agreement, after the SEC declares the registration statement related to the transaction effective, Aspire has committed to purchase up to $10 million of Atossa's common stock over 30 months, based on prevailing market prices over a period preceding each sale.
ATOS: 0.27 (+0.02)
Why Investors Still See Value in Alkermes, AMAG Pharmaceuticals, IDEXX Laboratories and Atossa Genetics?
PR Newswire - Thu May 19, 7:50AM CDT
The equities market is never short of surprises, and one sector that is always abounding of surprises is without doubt the Healthcare space. ActiveWallSt.com has uncovered four stocks in the Healthcare sector ahead of today's trading session: Alkermes PLC (NASDAQ: ALKS), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), and Atossa Genetics Inc. (NASDAQ: ATOS). Sign up for your complimentary alerts at:
ATOS: 0.27 (+0.02), AMAG: 27.02 (+0.49), IDXX: 98.07 (+4.56), ALKS: 49.56 (-0.34)
Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update
Marketwire Canada - Thu May 05, 3:01PM CDT
Conference Call to Be Held Today at 4:30 pm Eastern Time
ATOS: 0.27 (+0.02)
Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment
PR Newswire - Wed May 04, 5:42PM CDT
This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 393 pages. The personalized medicine (global & USA) market is presented as follows:
ATOS: 0.27 (+0.02), AMGN: 174.76 (+0.60)
Atossa Genetics to Host First Quarter 2016 Financial Results and Company Update Conference Call on Thursday, May 5, 2016
Marketwired - Tue May 03, 7:00AM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will host a conference call on Thursday May 5, 2016 at 4:30 pm eastern time to review First Quarter ended March 31, 2016 financial results and provide a company update. Following management's formal remarks, there will be a question and answer session.
ATOS: 0.27 (+0.02)
Atossa Genetics Announces 2015 Financial Results and Provides Company Update
Marketwired - Wed Mar 30, 3:01PM CDT
Atossa Genetics Inc. (NASDAQ: ATOS) today announced 2015 financial results and provided an update on recent company developments.
ATOS: 0.27 (+0.02)
Atossa Genetics to Host 2015 Financial Results and Company Update Conference Call on Wednesday, March 30, 2016
Marketwired - Fri Mar 25, 7:00AM CDT
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will host a conference call on Wednesday, March 30, 2016 at 4:30 pm eastern time to review 2015 financial results and provide a company update. Following management's formal remarks, there will be a question and answer session.
ATOS: 0.27 (+0.02)
Molecular Diagnostics Cancer Oncology - Global Market Size, Strategy & Forecasts - 2016 to 2019
M2 - Wed Jan 27, 9:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/phchgt/molecular) has announced the addition of the "Molecular Diagnostics Cancer Oncology - Global Market Size, Strategy and Forecasts - 2016 to 2019" report to their offering. A market that just keeps on growing. Molecular Diagnostics is positioned to directly benefit from the explosion in genomics knowledge. A range of dynamic trends are pushing market growth and company valuations. Trends include: - Personalized medicine - Pharmacogenomics - Pathogen evolution - Next generation sequencing - Emergence of new economies with large markets - Greater understanding of the role of genetic material in Disease and Health Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Companies Mentioned: - 14M Genomics - 23andMe - Abbott Laboratories - Abcam - ACT Genomics - Adaptive Biotechnologies - Aegis Sciences - Agena Bioscience - Agendia - Agilent/Dako - AltheaDx - Amarantus - Ariosa Diagnostics - Atossa Genetics - Baylor College of Medicin - Becton, Dickinson & Co. - Biofortuna - Biological Dynamics - BioMerieux - BioReference Laboratories, Inc. - (50 Others) Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Molecular Diagnostics Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summar For more information visit http://www.researchandmarkets.com/research/phchgt/molecular
ATOS: 0.27 (+0.02), ABT: 45.29 (unch), BDX: 176.78 (+0.78)
Global Medical Laboratory Services Strategies, Trends and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/kww8xj/medical) has announced the addition of the "Medical Laboratory Services Strategies, Trends and Forecasts 2016 to 2019 - Global Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Trends like: - changing demographics - emerging economies and global prosperity - biotechnology advances in genetics - pathogen evolution - climate change - globalization - automation Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Medical Laboratory Services Strategies, Trends and Forecasts 2015 to 2019 - Global Version provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. The Future of the Clinical Laboratory Companies Mentioned - 35 of the 100 Companies - 23andMe - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - ACM Medical Laboratory - ACT Genomics - Adaptive Biotechnologies - Adicon Clinical Laboratories, Inc. - Aegis Sciences - Agena Bioscience - Alere Inc - Amarantus - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Atossa Genetics - Aurora Diagnostics, LLC - Baylor College of Medicin - Biofortuna - Biomnis (France) - BioReference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caprion - CareDx - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Claritas Genomics - Claymon Biomnis Laboratories Ltd. - Clinical Reference Laboratory, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Cypher Genomics - Cytogenetics For more information visit http://www.researchandmarkets.com/research/kww8xj/medical
ATOS: 0.27 (+0.02), AXDX: 20.52 (+0.87), ALR: 36.97 (-0.53), ARDX: 10.50 (-0.18)
Global Molecular Diagnostics Market Size, Strategies and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/w2l7rl/molecular) has announced the addition of the "Molecular Diagnostics Global Market Size, Strategies and Forecasts 2016 to 2019 " report to their offering. A market that just keeps on growing. Molecular Diagnostics is positioned to directly benefit from the explosion in genomics knowledge. A range of dynamic trends are pushing market growth and company valuations. Trends like: - personalized medicine - pharmacogenomics - pathogen evolution - next generation sequencing - emergence of new economies with large markets - greater understanding of the role of genetic material in Disease and Health Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. The report data is designed to be used! The unit volumes of tests performed is presented. Use our pricing scenarios or use your own. Project your market share and your price to reliably generate revenue forecasts or understand your own current market share position. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Infectious Disease, Genetic Testing, Oncology Testing. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Molecular Diagnostics Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary Companies Mentioned - 14M Genomics - 23andMe - Abbott Laboratories - Abcam - Accelerate Diagnostics - AltheaDx - Atossa Genetics - Baylor College of Medicin - Becton, Dickinson & Co. - BioReference Laboratories, Inc. - bioM?rieux - Caprion - Cepheid - Claritas Genomics - Cypher Genomics - Cytogenetics - Diagnovus - Enzo Biochem - Epic Sciences - Foundation Medicine - Genomic Health - Genomic Vision - Good Start Genetics - Google - Great Basin Scientific - Grifols - Glyconics - Hologic - Premaitha - QuantRx? Biomedical - Quidel - Qvella - Response Genetics - Roche Molecular Diagnostics - Rosetta For more information visit http://www.researchandmarkets.com/research/w2l7rl/molecular
ATOS: 0.27 (+0.02), ABT: 45.29 (unch), BDX: 176.78 (+0.78), GBSNU: 16.22 (-0.28), FMI: 23.72 (+0.35), ENZ: 6.72 (-0.25), AXDX: 20.52 (+0.87), CPHD: 36.76 (+1.43), HOLX: 38.98 (+0.49), GHDX: 30.34 (+1.31)
Atossa Genetics Completes Sale of Its Wholly-Owned Subsidiary The National Reference Laboratory for Breast Health, Inc.
Marketwired - Thu Dec 17, 7:30AM CST
Atossa Genetics Inc. (NASDAQ: ATOS), a healthcare company focused on developing locally-administered pharmaceuticals for the treatment of pre-cancerous conditions and early stage breast cancer, today announced that on December 16, 2015, it entered into a Stock Purchase Agreement with NRL Investment Group, LLC, an unrelated entity. Under the agreement, Atossa sold to the NRL Group 100% of its shares of Common Stock in its wholly-owned subsidiary, the National Reference Laboratory for Breast Health, Inc. (the "NRLBH"
, while retaining 19% ownership through Preferred Stock. Atossa received $50,000 on December 16, 2015, for the sale of the Common Stock and the right to receive, commencing in December 2016, monthly earn-out payments equal to 6% of gross revenue of the NRLBH, up to a total of $10,000,000. Atossa also has the right in four years to sell its Preferred Stock to the NRL Group for the greater of $4,000,000 or fair market value. As a result of the transaction, the NRL Group is taking over the management, operations and related costs of the NRLBH. ATOS: 0.27 (+0.02)
Atossa Genetics Announces Third Quarter 2015 Financial Results and Provides Company Update
Marketwired - Thu Nov 12, 3:01PM CST
Atossa Genetics, Inc. (NASDAQ: ATOS) today announced third quarter 2015 financial results and provided an update on recent company developments.
ATOS: 0.27 (+0.02)
Atossa Genetics to Announce Third Quarter 2015 Financial Results and Provide a Company Update on Thursday, November 12, 2015
Marketwired - Tue Nov 10, 7:01AM CST
Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will issue financial results and corporate developments for the Third Quarter ended September 30, 2015, following the market close on Thursday, November 12, 2015.
ATOS: 0.27 (+0.02)
Global Breast Cancer Pipeline Review 2015
M2 - Tue Nov 03, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/3xkrvl/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Breast Cancer diagnostic tests pipeline products. Scope - Extensive coverage of the Breast Cancer diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Breast Cancer diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Breast Cancer - Pipeline Products under Development by Companies 5 Breast Cancer Companies and Product Overview 6 Breast Cancer- Recent Developments 7 Appendix Companies Mentioned - 35 of the 150 Companies Featured - A&G Pharmaceutical, Inc. - Abbott Diagnostics - Abcodia Ltd. - Abviva, Inc. - Accelerated Medical Diagnostics - Acobiom - Advanced Cell Diagnostics, Inc. - Affichem SA - AIT Austrian Institute of Technology GmbH - Almac Diagnostics Limited - Amarantus Bioscience Holdings, Inc. - AngioGenex, Inc. - Armune BioScience, Inc. - Arno Therapeutics, Inc. - AroCell AB - ArtemixRx - Ascendant Diagnostics, LLC - Assurance Biosciences, Inc. - Atossa Genetics, Inc. - Autoimmune Technologies, LLC - Ayanda Biosystems S.A. - Becton, Dickinson and Company - Bio Gene Ltd. - BioAffinity Technologies, Inc. - Biocrates Life Sciences AG - Biodesix Inc. - BioMarCare Technologies Ltd. - BioMark Diagnostics Inc. - BioMark Technologies Inc. - BioMarker Strategies, LLC - bioMerieux S.A. - Biosceptre (Aust) Pty Ltd - BioSystems International - bioTheranostics, Inc. - Boston College For more information visit http://www.researchandmarkets.com/research/3x...ast_cancer
ATOS: 0.27 (+0.02)
Atossa Genetics names Janet Rose Rea, MSPH as VP Regulatory Affairs and Quality
M2 - Thu Oct 15, 3:05AM CDT
Healthcare company Atossa Genetics (NASDAQ:ATOS) revealed on Wednesday the appointment of Janet Rose Rea, MSPH as VP Regulatory Affairs and Quality with effect from 12 October 2015.
ATOS: 0.27 (+0.02)
